← Leaderboards
Cathy A Swindlehurst
Novomedix, Inc.
$5,237,862
Attributed
$7,726,725
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,726,725 · 11
By mechanism
R44$3,959,666 · 2
R43$3,267,059 · 8
SB1$500,000 · 1
Top collaborators
- Anindita Das4 shared
- Fadi N Salloum4 shared
- Kimberly J Payne2 shared
- David Joseph Lefer1 shared
- Luis Marrero1 shared
- Patricia Janet Sime1 shared
- Thomas Henry Thatcher1 shared
Most similar at Novomedix, Inc.
Same institution · by research overlap
- Thomas Henry Thatcher$102,291
- Luis Marrero$157,181
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsSmall MoleculeLeadIn VivoToxic EffectPharmaceutical PreparationsScale UpIn VitroSafetyAnimal ModelMalignant NeoplasmsDoseOralPhase I Clinical TrialsFutureCessation Of LifePropertyAnimalsCellsSurvival RateMouse ModelPreventRouteProgesterone Receptors
Grant awards (16)
Arthrofibrosis control using small molecule inhibitors of interleukin-11$314,362
R43 · FY2025 · AR · contact PI
Definitive (GLP) Toxicity and Toxicology Studies for a Novel Small Molecule for Protection Against Cardiotoxicity in Triple Negative Breast Cancer$500,000
SB1 · FY2024 · HL · contact PI
Novel oral small molecules for progressive pulmonary fibrosis$306,872
R43 · FY2024 · HL · contact PI
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$930,592
R44 · FY2023 · HL · contact PI
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$1,062,913
R44 · FY2022 · HL · contact PI
Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease$375,000
R43 · FY2021 · HL · contact PI
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$375,001
R43 · FY2019 · HL · contact PI
Novel antifibrotic small molecules for the treatment of heart failure$300,000
R43 · FY2016 · HL · contact PI
The optimization of compounds that selectively inhibit protein synthesis for the$339,734
R44 · FY2014 · CA · contact PI
The optimization of compounds that selectively inhibit protein synthesis for the$833,819
R44 · FY2013 · CA · contact PI
Development of novel small molecule drugs for the treatment of high risk B-ALL$93,796
R43 · FY2013 · CA · contact PI
The optimization of compounds that selectively inhibit protein synthesis for the$792,608
R44 · FY2012 · CA · contact PI
Development of novel small molecule drugs for the treatment of high risk B-ALL$202,398
R43 · FY2012 · CA · contact PI
Optimization of compounds that selectively inhibit protein synthesis for the trea$300,236
R43 · FY2010 · CA · contact PI
Discovery and Development of Compounds to Enhance b-cell Number and Function$482,697
R43 · FY2008 · DK · contact PI
Discovery and Development of Compounds to Enhance b-cell Number and Function$516,697
R43 · FY2007 · DK · contact PI